Reverset is a
nucleoside analog reverse transcriptase inhibitor that is being developed as a once-daily oral HIV therapy by Incyte Corporation and Pharmasset, Inc.
Reverset is a
nucleoside analog (in the same class as AZT, 3TC, abacavir, tenofovir, and others), but is active against most of the viruses resistant to the approved antiretrovirals, as well as against wild-type, non-resistant virus.
BCH-10618 (DOTC)
nucleoside analog RT inhibitor Preclinical
Professor Glover's presentation at the NYAS will describe research into novel
nucleoside analogs that lead to robust checkpoint arrest at the G2/M phase of the cell cycle.
Two Cyclacel drugs are in Phase II trials: sapacitabine (CYC682), an orally-available, cell cycle modulating
nucleoside analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, for the treatment of lung cancer.
Sapacitabine (CYC682), an orally-available, cell cycle modulating
nucleoside analog, is in Phase II trials for the treatment of cutaneous T-cell lymphoma (CTCL) and Phase I trials in patients with hematologic malignancies.
This is the way tenofovir expanded access works in France, where the drug is recommended for patients with
nucleoside analog intolerance or with
nucleoside analog-resistant HIV, as demonstrated by resistance assays.
Patients must also have failed treatment with at least two protease inhibitors (PIs) or one PI and one non
nucleoside analog reverse transcriptase inhibitor.
Sapacitabine (CYC682) is an orally-available, cell cycle modulating
nucleoside analog in Phase I clinical trials for the treatment of cancer.
The active ingredient of ARYS-01 Cream is Sorivudine, an antiviral
nucleoside analog which was originally discovered by Yamasa Corporation of Chiba, Japan, and is being developed as a topical formulation by Janus under a joint development agreement with aRigen Inc.
The survey also found that combinations including the NNRTI drug class were the most popular to start with [as opposed to either protease inhibitors, or the triple
nucleoside analog treatment with abacavir].
Nasdaq: CYCC; Nasdaq: CYCCP) announced today interim results from a Phase I pharmacologic trial of sapacitabine (CYC682), a novel orally-available
nucleoside analog, in patients with advanced leukemias or myelodysplastic syndromes (MDS).
